Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)

Trial Profile

A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KSI 301 (Primary)
  • Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kodiak Sciences
  • Most Recent Events

    • 11 Oct 2019 Results presented in the Kodiak Sciences media release.
    • 11 Oct 2019 According to a Kodiak Sciences media release, data from this trial were presented at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day by Charles C. Wykoff, M.D, Ph.D., a clinical investigator in the study.
    • 15 Sep 2019 According to a Kodiak Sciences media release, data from this trial will be presented at the American Academy of Ophthalmology Retina Subspecialty Day on October 11.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top